Search

Search Results

• 

  34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo^1|2, Bruna Dalmasso³, Maria Chiara Scaini⁴, Laura Cendron⁵, Monica Rodolfo⁶, Ilaria Mattavelli⁷, Elena Tamborini⁸, Francesca Collina⁹, Gerardo Ferrara, Gabriele Madonna¹⁰, Carlo Cota¹¹, Elisa Melucci¹², Stefania Tommasi¹³, Martina Ubaldi¹⁴, Roberta Depenni¹⁵, Andrea Carugno¹⁶, Riccardo Marconcini¹⁷, Laura Orgiano¹⁸, Maurizio Lombardo¹⁹, Simona Sola²⁰, Cristina Pellegrini²¹, Francesca Castiglione²², Matteo Gasparotto^5|23, Alireza Jorkesh⁵, Stefania Pellegrini⁴, Edoardo Raposio¹, Andrea Boutros², Enrica Teresa Tanda², Michele Guida²⁵, Pietro Quaglino²⁶, Giuseppe Palmieri²⁷, Daniela Massi²², Paolo Antonio Ascierto¹⁰, Mario Mandalà*²⁸, Chiara Menin*⁴, Paola Ghiorzo*²⁴, Lorenza Pastorino*²⁴, for the Italian Melanoma Intergroup²⁹ | ¹Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; ²IRCCS Ospedale Policlinico San Martino, Genova; ³IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; ⁴Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; ⁵Department of Biology, University of Padua, Padua; ⁶Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁷Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁸Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁹Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; ¹⁰Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; ¹¹Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; ¹²Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; ¹³Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; ¹⁴Unit of Medical Oncology, University of Perugia; ¹⁵Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; ¹⁶Department of Medicine and Surgery, University of Insubria, Varese; ¹⁷Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; ¹⁸Department of Medical Oncology, University of Cagliari, Cagliari; ¹⁹Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; ²⁰Surgical Pathology, Galliera Hospital, Genoa; ²¹Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; ²²Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; ²³Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ²⁴Department of Internal Medicine and Medical Specialties, University of Genoa; ²⁵Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; ²⁶Dermatology Clinic, Department of Medical Sciences, University of Turin; ²⁷Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; ²⁸University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; ²⁹Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10776

  296
• 

  01 | End-of-life care in advanced melanoma and other skin cancers: a retrospective cohort from an Italian comprehensive cancer center Michela De Mattia¹, Enrica Teresa Tanda³, Andrea Boutros², Virginia Delucchi⁵, Eva Blondeaux⁵, Agostina Lagodin D’Amato¹, Irene Giannubilo¹, Lucia Del Mastro^1|2, Paolo Pronzato³, Francesco Spagnolo^3|4, Claudia Bighin³ | ¹Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova; ²U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova; ³U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova; ⁴Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate, Università di Genova, Genova; ⁵U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10743

  416
• 

  03 | Pancreatic cancer burden in Italian CDKN2a-positive families followed for up to 25 years Eleonora Allavena^1|2, Bruna Dalmasso², Andrea Gambino², Francesca Barbero², Irene Vanni², Cansu Gorgun¹, Francesco Spagnolo^2|4, Enrica Tanda³, Andrea Boutros³, William Bruno^1|2, Lorenza Pastorino^1|2, Paola Ghiorzo^1|2 | ¹Department of Internal Medicine and Medical Specialties - DiMI, University of Genoa; ²Cancer Genetics Unit, IRCCS Ospedale Policlinico San Martino, Genoa; ³Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genoa; ⁴Department of Surgical and Diagnostic Integrated Sciences, University of Genoa, Genoa, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10745

  334